focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTreatt Regulatory News (TET)

Share Price Information for Treatt (TET)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 487.50
Bid: 483.00
Ask: 489.50
Change: 0.00 (0.00%)
Spread: 6.50 (1.346%)
Open: 487.50
High: 487.50
Low: 487.50
Prev. Close: 487.50
TET Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half Year Trading Update & Notice of Results

10 Apr 2024 07:00

RNS Number : 9365J
Treatt PLC
10 April 2024
 

 

10 April 2024

 

TREATT PLC

("Treatt" or "the Group")

 

Half Year Trading Update and Notice of Results

Solid performance in H1 2024, with sales accelerating in the second quarter and year-on-year profit growth

Treatt, the manufacturer and supplier of a diverse and sustainable portfolio of natural extracts and ingredients for the beverage, flavour and fragrance industries, announces the following trading update for the half year ended 31 March 2024 (the "Period").

HIGHLIGHTS:

· Profit before tax and exceptional items (PBTE) expected to be marginally ahead of prior year at c.£7.5m (H1 2023: £7.3m).

· H1 revenue of £72.1m (H1 2023: £76.0m), reflecting a subdued Q1 from the impact of destocking as expected and previously indicated; and an acceleration in Q2, with sales growing by 5.1% (7.7% in constant currency) compared to the same quarter in FY 2023.

· New wins in Premium products and in China, with both areas growing during H1.

· Improved net operating margin of c.11.0% (H1 2023: 10.1%), reflecting embedded cost disciplines and self-help measures

· Net debt unchanged from 30 September 2023 at £10.3m (FY 2023: £10.4m), reflecting higher citrus commodity prices and high receivables at period end from strong March sales; however good cash generation expected in H2 as receivables convert to cash

· Looking to H2, we have a solid sales order book and healthy sales pipeline

· H2 full year PBTE anticipated to be in line with the Board's expectations.

H1 2024 Performance

Revenue for the half year declined by 5.1% (2.7% decline in constant currency) to £72.1m (FY 2023: £76.0m) as anticipated. Q1, which is typically our quietest quarter, saw a decline year on year due to destocking, however sales were 5.1% ahead (7.7% in constant currency) in Q2 as destocking softened, as expected.

Heritage sales declined by 6.0% (constant currency) as citrus customers elected for cheaper alternatives because of sustained high orange oil prices. Despite this, we continue to support our customers with innovative and differentiating solutions. Within Heritage, Synthetic Aroma was up 3.9% (constant currency), which we consider to be reflective of demand returning in this category which was impacted by destocking in FY23.

Our higher margin Premium categories grew 11.6% (constant currency), with multiple wins in Tea in the North American market. Premium is typically H2 weighted, and as such we expect further sales and margin growth in the second half.

In New Markets, China grew 3.3% (constant currency), securing further wins in leading local beverage brands and we have established a broader base of local manufacturing partners. In line with our strategic ambition we have commenced the scale up of our global Treattzest manufacturing capacity, and this product will be relaunched in April.

Balance sheet

The Group ended the half year with net debt of £10.3m (FY 2023: £10.4m). We continue to focus on working capital management and have successfully reduced inventory volume by 5.6% since September 2023 (16.7% lower than the comparable period), offset by higher commodity prices and seasonal build for strategic and premium demand. An increase in receivables reflects the strong finish to the half year trading and we anticipate a reduction in net debt in the second half, in line with Board expectations.

Ryan Govender, Interim CEO, commented:

"Treatt delivered a robust performance in the first half, making good progress in line with our strategic goals. We are particularly pleased with progress in China, where we continued to invest and consolidate our position, and in our higher margin Premium categories where we have a number of active pipeline opportunities. Momentum in the second quarter was strong, and we recorded our highest ever monthly revenue in March.

As we enter the second half, we are encouraged by our solid order book and healthy sales pipeline. The Board continues to expect to report full year PBTE in line with expectations."

Notice of results

Treatt's results for the half year ended 31 March 2024 are expected to be announced on 14 May 2024.

Treatt plc +44 (0)1284 702500

Ryan Govender Interim Chief Executive Officer

Alison Sleight Interim Chief Financial Officer

 

Joint Brokers

Investec Bank Plc +44 (0)20 7597 5970

Patrick Robb

David Anderson

 

Peel Hunt LLP +44 (0) 20 7418 8900

George Sellar

Mike Burke

 

Financial PR

MHP +44(0) 20 3128 8100

Tim Rowntree Treatt@mhpgroup.com

Eleni Menikou 

Catherine Chapman

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFSDSAIAIIS
Date   Source Headline
27th Nov 20187:00 amRNSFinal Results
16th Nov 201812:07 pmRNSSecond Price Monitoring Extn
16th Nov 201812:02 pmRNSPrice Monitoring Extension
14th Nov 201812:13 pmRNSHolding(s) in Company
13th Nov 20184:35 pmRNSPrice Monitoring Extension
9th Nov 20184:40 pmRNSSecond Price Monitoring Extn
9th Nov 20184:35 pmRNSPrice Monitoring Extension
6th Nov 20183:44 pmRNSHolding(s) in Company
16th Oct 20189:30 amRNSBoard Change
12th Oct 201812:07 pmRNSSecond Price Monitoring Extn
12th Oct 201812:02 pmRNSPrice Monitoring Extension
10th Oct 201812:07 pmRNSSecond Price Monitoring Extn
10th Oct 201812:02 pmRNSPrice Monitoring Extension
8th Oct 201812:07 pmRNSSecond Price Monitoring Extn
8th Oct 201812:02 pmRNSPrice Monitoring Extension
2nd Oct 20185:30 pmRNSDirector/PDMR Shareholding
2nd Oct 20187:00 amRNSTrading Update
1st Oct 20184:51 pmRNSTotal Voting Rights
7th Sep 20184:35 pmRNSPrice Monitoring Extension
3rd Sep 20184:18 pmRNSDirector/PDMR Shareholding
3rd Sep 20188:58 amRNSHolding(s) in Company
23rd Aug 20184:19 pmRNSDirector/PDMR Shareholding
20th Aug 20181:41 pmRNSDirector/PDMR Shareholding
8th Aug 20184:00 pmRNSHolding(s) in Company
10th Jul 20184:52 pmRNSHolding(s) in Company
9th Jul 20183:32 pmRNSDirector/PDMR Shareholding
5th Jul 201812:11 pmRNSHolding(s) in Company
4th Jul 201812:08 pmRNSTotal Voting Rights
13th Jun 201810:14 amRNSDirector/PDMR Shareholding
11th Jun 20184:47 pmRNSHolding(s) in Company
8th Jun 20187:00 amRNSBlock Listing Application
5th Jun 201812:07 pmRNSBlock Listing Six Monthly Return - Replacement
4th Jun 20185:00 pmRNSHolding(s) in Company
4th Jun 201810:42 amRNSBlock Listing Six Monthly Return
1st Jun 201811:30 amRNSTotal Voting Rights
1st Jun 201811:24 amRNSHolding(s) in Company
31st May 20183:50 pmRNSCompletion of disposal
18th May 201811:13 amRNSDirector/PDMR Shareholding
11th May 20184:50 pmRNSDirector/PDMR Shareholding
8th May 20187:19 amRNSHalf-year Report
8th May 20187:15 amRNSDisposal
30th Apr 201812:20 pmRNSTotal Voting Rights and Capital
27th Apr 20184:39 pmRNSHolding(s) in Company
11th Apr 20183:56 pmRNSHolding(s) in Company
6th Apr 20181:31 pmRNSHolding(s) in Company
5th Apr 20187:00 amRNSTrading Update
26th Mar 20184:41 pmRNSDirector/PDMR Shareholding
26th Mar 20184:41 pmRNSDirector/PDMR Shareholding
5th Mar 20183:03 pmRNSDirector/PDMR Shareholding
8th Feb 20183:08 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.